Global Obesity Management Market is valued at approximately USD 788.6 million in 2021 and is anticipated to grow with a healthy growth rate of more than 5.00 % over the forecast period 2022-2028. Obesity Management includes losing weight which can be achieved by a combination of a healthier diet, increased physical activity, and other behavioural adjustments. Some people may benefit from weight-management programmes in order to lose weight or avoid regaining it. The increase in the global obese population and strategic collaborations among the players has led to the adoption of Obesity Management across the forecast period. For Instance: In January 2018, H2-Pharma announced a partnership with Cheplapharm Arzneimittel GmbH and re-launched XENICAL 120 mg capsules via its newly formed branded division. Also, with the increasing obesity in children and adolescents and rise in awareness regarding health issues, the adoption & demand for Obesity Management is likely to increase the market growth during the forecast period. However, high cost of surgeries and safety concerns about Obesity Management drugs impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Obesity Management Market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to the rising health issue resulting in numerous diseases. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2022-2028. Factors such as changes in lifestyle, diet, and exercise habits would create lucrative growth prospects for the Obesity Management Market across Asia-Pacific region.

Major market players included in this report are:

Weight watchers international (us)

Jenny craig (us)

Atkins nutritionals, inc. (us),

Herbalife ltd. (us),

Nutrisystem ltd. (us),

Kellogg company (us),

Ethicon, inc. (us),

Covidien, plc. (us),

Apollo endosurgery (us),

Olympus corporation (olympus) (japan)

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug:

Bupropion and Naltrexone

Orlistat

Lorcaserin

Phentermine and Topiramate

Liraglutide

By Surgery:

Gastric Bypass Surgery

Adjustable Gastric Banding Surgery

Gastric Sleeve Surgery

Duodenal Switch Surgery

Other

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Obesity Management Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors